Novartis Investigative Site

Shah Alam, Selangor 40000

0 studies enrolling now · 3 studies all time

What they study most

Age-related Macular Degeneration, Central Retinal Vein Occlusion, Neovascular Age-related Macular Degeneration

Studies at this site

• Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) — Completed
• An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study — Completed
• Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion — Stopped early